Senior Director of Data Science, BigHat Biosciences
Office located in San Mateo, CA
Antibody discovery & engineering platform
Job no longer available
Antibody discovery & engineering platform
21-100 employees
Job no longer available
Office located in San Mateo, CA
21-100 employees
Company mission
To improve human health by making it far easier to design advanced, next-generation antibody therapeutics.
Jump to section
Company mission
To improve human health by making it far easier to design advanced, next-generation antibody therapeutics.
Our take
Melding genetics and code, BigHat Biosciences is a protein therapeutics company that develops antibodies for the medical industry using machine learning and AI. Established in 2019, the company combines advanced computational models with an automated wet lab to design and test antibody therapies more quickly than traditional methods. Its technology has been applied to a range of use cases too, including efforts during the pandemic to accelerate vaccine and therapeutic development.
The platform has particular value in helping develop treatment for complex and hard-to-treat diseases such as Alzheimer's disease, where designing effective biologic drugs is especially challenging. To support this work, BigHat has partnered with major pharmaceutical companies including Merck & Co, and Amgen to apply its AI-driven antibody design platform to drug discovery and development.
More recently, BigHat has continued to expand its partnerships and pipeline as interest in AI-enabled drug discovery grows. The company has also collaborated with Eli Lilly and Company to help develop next-generation antibody therapeutics using its Milliner platform, while also advancing its own internal programmes in areas such as oncology. With candidates including a gastrointestinal cancer and antibody-drug conjugate expected to enter clinical trials in 2026, BigHat is positioning itself not only as a technology partner for pharmaceutical companies but as as developer of its own next-generation biologic medicines.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Culture of excellence and growth
- Swift promotions with clear standards
- Autonomy and responsibility
- Fair compensation and recognition
- True work life balance
Funding (last 2 of 3 rounds)
Jul 2022
$75m
SERIES B
Feb 2021
$19m
SERIES A
Total funding: $99.3m
This company has top investors
Leadership
Peyton Greenside
(Co-Founder, CEO & President)Peyton originally served as the CSO at BigHat before moving into the role of CEO in 2025. Previously, she was a Founding Scientific Advisor at VALIS.